Last reviewed · How we verify
Risperidone long acting injectables
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (maintenance treatment), Irritability associated with autism spectrum disorder.
At a glance
| Generic name | Risperidone long acting injectables |
|---|---|
| Also known as | Risperdal Consta |
| Sponsor | Janssen Korea, Ltd., Korea |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. The long-acting injectable formulation provides sustained drug delivery over weeks, improving medication adherence in chronic psychiatric conditions.
Approved indications
- Schizophrenia
- Bipolar I disorder (maintenance treatment)
- Irritability associated with autism spectrum disorder
Common side effects
- Injection site pain or reactions
- Weight gain
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Prolactin elevation (galactorrhea, amenorrhea)
- Sedation
- Orthostatic hypotension
- Metabolic syndrome (hyperglycemia, dyslipidemia)
Key clinical trials
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
- High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone (PHASE4)
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (PHASE1)
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
- Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (PHASE4)
- Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
- Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone long acting injectables CI brief — competitive landscape report
- Risperidone long acting injectables updates RSS · CI watch RSS
- Janssen Korea, Ltd., Korea portfolio CI